CN1108535A - 心脏基础液及其制备工艺 - Google Patents
心脏基础液及其制备工艺 Download PDFInfo
- Publication number
- CN1108535A CN1108535A CN 94116227 CN94116227A CN1108535A CN 1108535 A CN1108535 A CN 1108535A CN 94116227 CN94116227 CN 94116227 CN 94116227 A CN94116227 A CN 94116227A CN 1108535 A CN1108535 A CN 1108535A
- Authority
- CN
- China
- Prior art keywords
- potassium
- injection
- acid
- basal liquid
- dihydrogen phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于人体电解质的补充,并参与
心肌细胞能量代谢的注射液及制备工艺。其成分含
有醋酸钾、磷酸二氢钾、氢氧化钾、氧化镁、L-门冬氨
酸、L-苹果酸、山梨醇,以注射用水溶解。该产品能
有效地提高细胞内的钾镁离子量,对心肌有正性肌力
的作用,改善休克后的内环境,稳定血压,有利尿作
用,且有稳定细胞膜的作用,加强重碳酸盐的重吸收,
调节pH。
Description
本发明涉及一种用于人体电解质的补充,并参与心肌细胞能量代谢的注射液及其制备工艺。
目前临床所使用的基础液有GIK(含10%葡萄糖500ml,10%KCL22.5ml,普通胰岛素12IU)和1,6-二磷酸果糖(FDP)。GIK液是通过加强糖原合成的作用,使细胞外钾进入细胞内,糖原分解成丙酮酸,进入三梭酸循环,产生能量。组织缺氧时会对这一机制产生影响。内源性的FDP的葡萄糖氧化的中间产物,外源性的FDP不能进入细胞膜,而主要通过激活磷酸果糖激酶(PFK)的活性,抑制葡萄糖的无氧酵解,加快三梭酸循环的反应速度。PFK的活性与pH,和细胞外的钙离子水平有关,是一种条件型的酶。因此,在缺氧和酸中毒的情况下,这一机制也会受到抑制。
本发明的目的在于提供一种可有效提高细胞内的钾镁离子含量,对心肌有正性肌力作用的心脏基础液及其制备工艺。
本发明的组成及各成分的含量为:醋酸钾1.472g、磷酸二氢钾1.361g、氢氧化钾1.964g、氧化镁0.705g、L-门冬氨酸4.991g、L-苹果酸2.700g、山梨醇50.00g、注射用水900ml,共制成1000ml。其制备工艺为:称取上述含量之醋酸钾、磷酸二氢钾、氧化镁、L-门冬氨酸、L-萍果酸,依顺序溶于900ml注射用水,加热至70℃,搅拌,使完全溶解;再加入山梨醇、氢氧化钾,继续搅拌至溶解,按配制量加0.03%活性碳,搅匀,过滤,滤液添加注射用水使成全量1000ml,趁热滤过至澄明,灌封,以115℃热压灭菌30分钟即得。
下面结合实施例对本发明作详细描述。
称取醋酸钾1.427g、磷酸二氢钾1.361g、氧化镁0.705g、L-门冬氨酸4.991g、L-苹果酸2.700g,依顺序溶于900ml注射用水,加热至70℃,搅拌,使完全溶解。再加入山梨醇50.00g,氢氧化钾1.964g,继续搅拌至溶解。按配制量加0.03%活性碳,搅匀,过滤。滤液添加注射用水使成全量1000ml,趁热滤过至澄明,灌封,以115℃热压灭菌30分钟,制得规格250ml/瓶或500ml/瓶之产品。
基础液对提高细胞内的钾镁水平的作用机制是多方面的。苹果酸有稳定细胞膜的作用。门冬氨酸可作为载体,将细胞外的钾镁转移到细胞内,或腺粒体内。在缺氧不严重的情况下,这一机制不受影响。门冬氨酸参与苹果酸-门冬酸酸穿梭反应,加快处理还原型辅酶(NADH)转化为还原型辅助酶的过程,使丙酸酸还原成乳酸的过程受到抑制,有利于三梭酸循环的进行。在缺氧时,萍果酸是腺粒体内ATP的重要来源之一。苹果酸还可以使肾小球对重碳酸盐的重吸收增加,促进肝脏对血氨的代谢反应速度,使pH升高,处理酸中毒的能力加强。
本发明的优点:
(一)使用有机钾盐和体内镁的正常结合形式补充钾镁,含有门冬氨酸,可以作为钾镁离子的载体,将钾镁向细胞内转移,有效提高细胞内的钾镁离子含量,对心肌有正性肌力的作用,改善休克后的内环境,稳定血压,有利尿作用。
(二)有稳定细胞膜的作用,加强重碳酸盐的重吸收,调节pH。
(三)在补充细胞内电解质的同时,参与细胞内能量代谢。
Claims (2)
1、一种心脏基础液,其特征在于它的组成及各成分的含量为:醋酸钾1.472g、磷酸二氢钾1.361g、氢氧化钾1.964g、氧化镁0.705g、L-门冬氨酸4.991g、L-苹果酸2.700g、山梨醇50.00g、注射用水900ml,共制成1000ml。
2、一种心脏基础液的制备工艺,其特征在于:称取上述含量之醋酸钾、磷酸二氢钾、氧化镁、L-门冬氨酸、L-萍果酸,依顺序溶于900ml注射用水,加热至70℃,搅拌,使完全溶解;再加入山梨醇、氢氧化钾,继续搅拌至溶解,按配制量加0.03%活性碳,搅匀,过滤,滤液添加注射用水使成全量1000ml,趁热滤过至澄明,灌封,以115℃热压灭菌30分钟即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 94116227 CN1108535A (zh) | 1994-09-20 | 1994-09-20 | 心脏基础液及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 94116227 CN1108535A (zh) | 1994-09-20 | 1994-09-20 | 心脏基础液及其制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1108535A true CN1108535A (zh) | 1995-09-20 |
Family
ID=5037817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 94116227 Pending CN1108535A (zh) | 1994-09-20 | 1994-09-20 | 心脏基础液及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1108535A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1090483C (zh) * | 1997-07-31 | 2002-09-11 | 谢理峰 | 钾镁缓释片及生产方法 |
CN107468705A (zh) * | 2017-09-01 | 2017-12-15 | 济南康和医药科技有限公司 | 一种复方电解质葡萄糖注射液及其制备方法 |
-
1994
- 1994-09-20 CN CN 94116227 patent/CN1108535A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1090483C (zh) * | 1997-07-31 | 2002-09-11 | 谢理峰 | 钾镁缓释片及生产方法 |
CN107468705A (zh) * | 2017-09-01 | 2017-12-15 | 济南康和医药科技有限公司 | 一种复方电解质葡萄糖注射液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lemon | Is increased dietary protein necessary or beneficial for individuals with a physically active lifestyle? | |
Hammond et al. | The metabolism of γ-aminobutyrate and glucose in potassium ion-stimulated brain tissue in vitro | |
Krawiec et al. | Hormonal regulation of brain development. III. Effects of triiodothyronine and growth hormone on the biochemical changes in the cerebral cortex and cerebellum of neonatally thyroidectomized rats | |
WO2005123099A2 (en) | Methods and compositions for accelerating alcohol metabolism | |
EP0669083A2 (en) | Creatine beverage and producing process thereof | |
Taneja et al. | Effect of early iron deficiency in rat on the γ‐aminobutyric acid shunt in brain | |
EP1172373A2 (en) | Method for preparing zinc-oligopeptide easily absorbable by the human body | |
CN1108535A (zh) | 心脏基础液及其制备工艺 | |
Stocker et al. | Coupled oxidative phosphorylation in muscle of thyrotoxic patients | |
Mäkinen | Enzyme dynamics of a cariogenic streptococcus: the effect of xylitol and sorbitol | |
Cohen et al. | Enzymatic synthesis of 11C-pyruvic acid and 11C-L-lactic acid | |
Hetland et al. | Serum and erythrocyte zinc concentrations after prolonged heavy exercise | |
Luoma | Phosphorus translocation between enamel and Streptococcus mutans in the presence of sucrose and fluoride with observations on the acid phosphatase of S. mutans | |
Rajalakshmi et al. | Effects of different levels of dietary protein on brain glutamate dehydrogenase and decarboxylase in young albino rats | |
Linder | Other trace elements and the liver | |
JP2832009B2 (ja) | 酢酸発酵促進用組成物およびそれを用いる食酢の製造法 | |
Dow et al. | Steady-state oxidation of glucose in hyperthyroid and hypothyroid rats | |
Wilson | Metabolic abnormalities in uremia | |
Putnam et al. | The metabolism of DL-glutamic acid-1-C14 in man. | |
US3876783A (en) | Method of and composition for the treatment of acute intoxication | |
CN107441124A (zh) | 一种降糖口服液及其制备方法 | |
AU2021100653A4 (en) | Food supplement rich in biological ions for high-intensity outdoor sports | |
CN101596180A (zh) | 一种植物氨基酸型螯合钙、铁、锌的组合物及制备方法 | |
CN108464506A (zh) | 三酶一酵富微生物液的生产方法 | |
CN1122714C (zh) | 高钙醋 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |